Finanzas de AbbVie Inc. (ABBV)ABBVAbbVie Inc.

AbbVie Inc. (ABBV) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Immunology-SKYRIZI, accounting for 32.4% of total sales, equivalent to $5.50B. Other significant revenue streams include Immunology-RINVOQ and Neuroscience-Vraylar. Understanding this composition is critical for investors evaluating how ABBV navigates market cycles within the Pharmaceuticals industry.

Evaluating the bottom line, AbbVie Inc. maintains a gross margin of 74.74%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 39.57%, while the net margin is 21.28%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively ABBV converts its operational activities into shareholder value.

In the context of the broader market, ABBV competes directly with industry leaders such as JNJ and MRK. With a market capitalization of $500.94B, it holds a significant position in the sector. When comparing efficiency, ABBV's gross margin of 74.74% stands against JNJ's 68.17% and MRK's 74.64%. Such benchmarking helps identify whether AbbVie Inc. is trading at a premium or discount relative to its financial performance.

AbbVie reported a gross profit margin of 74.74% in Q2 2026, indicating strong profitability. The company has consistently increased its revenue, with Q2 2026 revenue at $16.99 billion, up from $15.00 billion in Q1 2026. The net income for Q2 2026 was $3.60 billion, showcasing strong earnings growth.